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Summary
CREB is a transcription factor that functions in glucose homeostasis, growth factor-dependent cell survival, and memory.
In this study, we describe a role of CREB in human cancer. CREB overexpression is associated with increased risk of
relapse and decreased event-free survival. CREB levels are elevated in blast cells from patients with acute myeloid leuke-
mia. To understand the role of CREB in leukemogenesis, we studied the biological consequences of CREB overexpression
in primary human leukemia cells, leukemia cell lines, and transgenic mice. Our results demonstrate that CREB promotes
abnormal proliferation and survival of myeloid cells in vitro and in vivo through upregulation of specific target genes. Thus,
we report that CREB is implicated in myeloid cell transformation.S I G N I F I C A N C E
Acute myeloid leukemia (AML) in adults has a 20% 5-year disease-free survival, despite treatment with aggressive cytotoxic chemo-
therapy. In this study, we show that CREB is overexpressed in primary myeloid leukemia cells in some AML patients and is associated
with poor initial outcome of clinical disease. CREB overexpression results in increased survival and proliferation of myeloid cells and
blast transformation of bone marrow progenitor cells from transgenic mice expressing CREB in the myeloid lineage. CREB transgenic
mice also develop myeloproliferative disease after one year. Thus, CREB acts as a proto-oncogene to regulate hematopoiesis and
contributes to the leukemia phenotype. Our results suggest that CREB-dependent pathways may serve as targets for directed thera-
pies in leukemia.Introduction
Leukemia is defined as uncontrolled proliferation of cells of the
hematopoietic lineage. The disease results from the accumula-
tion of mutations in oncogenes and tumor suppressor genes,
and the loss of equilibrium between proliferation and differenti-
ation of the hematopoietic progenitor cells (Dash and Gilliland,
2001; Haywitz and Greenberg, 1999; Kelly and Gilliland, 2002;
Tenen et al., 1997). Recent evidence suggests that overexpres-
sion of chromosomal translocations specific to leukemias,
such as PML-RARα or AML-ETO in mice, results in a pro-
longed latency or myeloproliferative syndrome without devel-
opment of acute leukemia (Rego and Pandolfi, 2002; Yuan et
al., 2001). Therefore, existence of additional genetic mutations
is necessary for the development of acute leukemia.
To this end, we sought to understand the signaling pathways
that regulate aberrant myelopoiesis. Myeloid leukemia cells ex-
press functional, high-affinity receptors for growth factors such
as granulocyte-macrophage colony stimulating factor (GM-
CSF) and interleukin-3 (IL-3). We previously demonstrated that
the cyclic adenosine monophosphate response element bind-CANCER CELL : APRIL 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INCing protein (CREB) is activated through phosphorylation at ser-
ine 133 in response to GM-CSF stimulation (Sakamoto et al.,
1994). Furthermore, activation of CREB is downstream of mito-
gen-activated protein kinase kinase (MEKK)- and pp90 ribo-
somal S6 kinase (RSK)-dependent pathways in myeloid leuke-
mic cells (Kwon et al., 2000; Lee et al., 1995). Since we
identified CREB as a downstream target of GM-CSF signaling
pathways, we examined the status of CREB expression in pri-
mary myeloid leukemia cells in bone marrow samples from pa-
tients with acute leukemia (Crans-Vargas et al., 2002). Bone
marrow samples from patients with acute myeloid or lymphoid
leukemias expressed higher detectable levels of CREB com-
pared to nonleukemic, remission, or control bone marrow
(Crans and Sakamoto, 2001; Crans-Vargas et al., 2002). There-
fore, our results demonstrated that CREB overexpression is
found in a subset of patients, and that CREB may play a role
in leukemogenesis.
CREB is a 43 kDa-basic/leucine zipper (bZip) transcription
factor that regulates gene expression through the activation of
cAMP-dependent or -independent signal transduction path-
ways. CREB binds to an octanucleotide cAMP response ele-. DOI 10.1016/j.ccr.2005.02.018 351
A R T I C L Ement (CRE) consensus sequence in promoters of target genes
as a homodimer or heterodimer with other members of the
CREB/ATF superfamily. Phosphorylation of CREB at serine 133
is essential for CREB-mediated transcription (Haywitz and
Greenberg, 1999; Kuo and Leiden, 1999; Lee et al., 1995; Sa-
kamoto et al., 1994; Wong and Sakamoto, 1995). CREB en-
hances both proliferation and survival in neuronal cells (Hay-
witz and Greenberg, 1999; Kuo and Leiden, 1999; Riccio et al.,
1999; Riccio and Ginty, 2002; Riccio et al., 1997).
To understand the role of CREB in the development of leuke-
mia, we studied the molecular and biological consequences of
CREB overexpression in primary leukemia cells, leukemia cell
lines, and transgenic mice. We also examined whether CREB
is critical for leukemia cell growth and survival using RNA inter-
ference. Our results demonstrated that CREB promotes abnor-
mal proliferation, cell cycle progression, and survival of myeloid
cells in vitro and in vivo through induction of specific target
genes. Furthermore, CREB overexpression in AML patients is
associated with relapse or persistent disease and may predict
a poor outcome in patients with AML.
Results
Elevated CREB expression and activation in bone
marrow cells from AML patients
To examine CREB expression and activation in primary AML
cells, Western blot analysis was performed with cell lysates
from five AML patients who were previously classified as
CREB-positive and two patients without leukemia (Table 1;
Crans-Vargas et al., 2002). We observed a 2- to 3-fold increase
in CREB expression and activation, compared to no expression
or low levels of CREB expression in the nonleukemic control
samples (Figure 1A and data not shown).
To determine whether increased CREB expression in primary
AML cells was due to increased transcription or posttransla-
tional modification, we performed quantitative real-time reverse
transcription PCR with mRNA obtained from the bone marrow
of eight AML patients that were CREB-positive by Western blot
analysis, as well as four normal samples. The mean expression
of CREB mRNA from AML patient samples was 2- to 3-fold
higher than control patients (p < 0.01; Figure 1B), which corre-
lated with protein levels quantitated using densitometry. There-Table 1. Immunophenotype, AML subtype, and CREB expression in leukemia cells from AML patients
Diagnosis CREB CD34 Other markers
Not leukemia
Non-Hodgkin’s lymphoma, off therapy, (11-year-old male) − − CD19 (13%), CD10 (16%), CD22 (0), CD34 (0)
Hodgkin’s lymphoma (13-year-old female) − − CD19 (12%), CD20 (7%), CD22 (14%), CD34 (0)
AML diagnosis
AML-M1 (25-year-old female) + + CD13 (97%), CD14 (6%), CD15 (27%), CD33 (84%), CD34 (79%), CD117
(76%)
AML-M4, relapse (14-year-old male) + − CD13 (83%), CD33 (46%), CD14 (36%), CD34 (100%), CD14 (81%), CD56
(16%)
AML-M4, diagnosis (17-year-old male) + − CD13 (56%), CD33 (99%), CD14 (32%), CD45 (100%), CD15 (95%),
CD117 (14%)
AML-M5a, diagnosis (33-year-old female) + − CD13 (11%), CD14 (0%), CD15 (93%), CD33 (98%), CD56 (8%), CD45
(100%)
AML-M4, diagnosis (50-year-old male) + + CD15 (36%), CD16 (3%), CD33 (90%), CD34 (47%), CD45 (low), CD117
(53%)352fore, both CREB mRNA and protein levels are increased in
CREB-positive AML cells.
To investigate whether the leukemic blast cells in the bone
marrow specifically express CREB, we performed immuno-
histochemistry with anti-CREB antisera on bone marrow bi-
opsy touch preparations obtained from CREB-positive and
-negative patients (as determined by Western blot analysis) or
normal bone marrow. Leukemic blasts from CREB-positive but
not controls had nuclear staining of CREB (Figure 1C). Our re-
sults indicate that overexpression of CREB occurs in the blast
cells from CREB-positive patients, but not those from CREB-
negative patients or normal bone marrow.
There was also no association between CD34, CD33, and
CREB expression on leukemic blast cells from patients who
were CREB-positive or -negative (Supplemental Table S1). All
of the blast cells from AML patients expressed CD33. Quanti-
tative real-time PCR with RNA from normal CD34+CD33−,
CD34+CD33+, and CD34−CD33+ cells and blast cells from
CREB-positive AML patients demonstrated a 2-fold increase in
CREB expression in AML CD34+CD33+ cells (p < 0.003) and
a 1.4-fold increase in CD34−CD33+ cells (p < 0.006) compared
to controls, but no difference in CD34+CD33− cells (p = 0.23,
Supplemental Figure S1). These results suggest that CREB ex-
pression is higher in CREB-positive leukemia stem cells com-
pared to normal cells.
Since both CREB protein and mRNA levels were increased
in CREB-positive primary AML cells, we postulated that CREB
could be amplified as with other oncogenes, e.g., myc. We per-
formed fluorescence in situ hybridization (FISH) on blast cells
from four CREB-overexpressing patients using a CREB-spe-
cific BAC clone. CREB has been previously localized to chro-
mosome 2q32.3-q34 (Taylor et al., 1990). In normal control
lymphocytes in metaphase and CREB nonamplified (negative)
bone marrow cells in interphase, the CREB BAC showed two
clear and unambiguous signals (Figure 1D, upper panels).
However, in the blast cells from three out of four AML patients
that overexpress CREB (CREB+), we detected three to four sig-
nals from one homolog and one signal from the other in over
250 interphase nuclei analyzed (Figure 1D, lower panels). Three
out of the four CREB-positive patients analyzed had a normal
karyotype with no evidence of aneuploidy or hyperdiploidy.
These results indicate that in certain patients, there are moreCANCER CELL : APRIL 2005
A R T I C L EFigure 1. CREB overexpression in patients with AML
A: Western blot analysis with lysates from five representative patients with
CREB-positive AML, and two individuals who were normal/without leuke-
mia (NL). The blots were probed with anti-CREB or phospho-CREB antisera
(UBI, Inc.).
B: Real-time RT-PCR analysis of CREB expression. The cDNAs from patients
with AML and patients without leukemia were subjected to real-time RT-
PCR with CREB-specific primers and probe. The results are expressed in
percentage, with expression of CREB mRNA in AML relative to that ob-
served in nonleukemia samples (which have been assigned the value of
100%). Error bars denote the standard deviation of each sample measured
in triplicate.
C: Immunohistochemistry performed on bone marrow biopsy touch preps
using anti-CREB antisera. Increased expression of CREB in the nucleus of
AML blasts was seen in CREB-positive patients, but not in AML patients with-
out CREB overexpression (CREB-negative) or normal neonatal bone
marrow.
D: FISH on normal metaphase from PHA-stimulated lymphocytes (upper
left) and interphase cells from CREB nonoverexpressing blast cells (upper
right) showing two distinct signals. Interphase cells from three different AML
patient samples with CREB overexpression (CREB+) show three signals from
one homolog and one from another (bottom panels; see arrows). CREB-
negative (CREB−) represents AML patients without CREB overexpression by
Western blot analysis.CANCER CELL : APRIL 2005activity was observed in the CREB-overexpressing cells,
E: Risk of relapse in 34 adult AML patients (left). Cumulative percentage of
patients relapsing or showing persistent disease after first induction chemo-
therapy was greater in those patients whose initial bone marrow overex-
pressed CREB (solid line, n = 24) compared to those not expressing CREB
(dashed line, n = 10); p = 0.001 by exact log rank test. The difference re-
mained significant (p = 0.01) after stratification on cytogenetic prognosis.
Relapse-free survival curves (right) show that the percentage remaining
alive without relapse or persistent disease was lower in those patients over-
expressing CREB; p = 0.0003 without stratification and p = 0.003 after stratifi-
cation on cytogenetics. For both figures, a vertical tick mark indicates a
censored observation. The differences in outcome between the CREB
groups were also statistically significant (p < 0.005 by likelihood ratio tests)
in Cox regression models that included age, gender, initial percent blasts,
WBC, and CD34+ percentage as potential covariates, and stratified on
cytogenetic prognosis.than the normal two copies of CREB, which may be one poten-
tial mechanism by which increased CREB expression occurs.
To evaluate whether CREB expression predicts outcome in
patients with AML, Kaplan-Meier analysis was performed on
data from 34 adult patients (median age 48 years, range 19–82;
Supplemental Table S1). Persistent disease and shorter time to
relapse (Figure 1E, left) was observed in the 24 CREB-positive
patients compared to the 10 not expressing CREB, both before
and after stratification on cytogenetics (p = 0.001 and p = 0.01,
respectively). Likewise, event-free survival (Figure 1E, right)
was worse in the CREB-positive group (p < 0.01 after stratifi-
cation on cytogenetics). Interestingly, all eight patients who
showed persistent disease after initial induction therapy were
CREB-positive. No variable other than CREB overexpression
had a significant association with risk of relapse or event-free
survival. Initial treatment, cytogenetics, AML subtype, age,
gender, initial white blood count, percent blast count, and per-
cent CD33+ and CD34+ cells were similar between the two
CREB groups. There was no strong evidence for an association
of overall survival with CREB expression (p = 0.11 after stratifi-
cation on cytogenetics). Our results suggest that CREB ex-
pression is associated with an increased risk of relapse or per-
sistent disease and decreased event-free survival.
CREB promotes growth and survival in leukemia cells
To study the biological significance of CREB overexpression in
vitro, we constructed an expression vector that contains the
hMRP8 promoter, which drives the expression of CREB cDNA
in cells of the myeloid lineage (Frantzen et al., 1993; Lagasse
and Weissman, 1992; Lagasse and Weissman, 1996; Lagasse
and Weissman, 1997; Roth et al., 1993; Yuan et al., 2001). The
advantage of using an endogenous promoter is to overexpress
CREB in vitro and in vivo at levels similar to those found in
CREB-positive primary leukemia blast cells. The hMRP8-CREB
construct was stably transfected into the myeloid leukemic cell
lines NFS60 and K562. Clones expressing the highest levels of
CREB protein were isolated (Figure 2A; top panel). We then
confirmed that CREB was activated in these clones using anti-
phospho CREB antisera (Figure 2A; middle panel).
To test the transcriptional activity of overexpressed CREB,
we transfected K562 clones or control cells with a reporter
construct containing 600 nucleotides (nt) of the human early
growth response gene-1 (egr-1) promoter, which contains a
CRE consensus sequence fused to the chloramphenicol acetyl
transferase (CAT) reporter gene. A 3- to 4-fold increase in CAT353
A R T I C L EFigure 2. Overexpression of CREB in vitro
A: NFS60 (right) and K562 cells express CREB under the control of the myeloid-specific HMRP8 promoter.
B: Increased transcriptional activity in CREB-expressing cells. A statistically significant increase in fold stimulation was observed with CREB-overexpressing
cells compared to control cells (represented by *).354 CANCER CELL : APRIL 2005
A R T I C L Eleukemia cells. CREB transgenic mice, we performed colony assays in methyl-
C: Increased cell growth and survival in CREB-overexpressing cells. NFS60 and K562 cells stably transfected with wild-type CREB. K562 cell numbers were
analyzed in exponentially growing cultures (y axis = cells/ml) (a). For other growth curves (b and c), viable cells were counted for six days in growth media.
For survival experiments (d and e), cells were plated in BSA. CREB overexpression resulted in increased cell growth once maximum density was reached
(b and d), and increased cell survival (c and e).
D: CREB overexpression results in increased proliferation. NFS60 parental and CREB clones were synchronized by serum starvation and pulsed with BrdU.
CREB overexpression resulted in a statistically significant increase in the numbers of cells in S phase (graph and table). These experiments were performed
in triplicate on three separate days.
E: CREB overexpression inhibits differentiation. K562 parental and CREB-overexpressing cells were induced to differentiate by sodium butyrate. The left
graph represents the percentage of cells that were benzidine-positive. A statistically significant difference in the number of differentiated cells between
the control and the CREB-expressing clones was seen (indicated by *). Growth curves show that butyrate does not inhibit proliferation or increase cell
death (right).
F: CREB siRNA inhibits growth and survival of myeloid leukemia cells. a: K562 growth curve. K562 cells were transfected with 100 nM 3# CREB siRNA or control
at 0, 24, and 48 hr. Western blot analysis shows 75% and 90% inhibition of CREB with siRNA at 48 and 72 hr (* represents p < 0.038), respectively. b: TF-1
growth curve. TF-1 cells were treated with 100 nM 3# CREB siRNA. Western blot analysis demonstrates greater than 50% and 90% inhibition at 24 and 48 (*
represents p < 0.0001) or 72 (* represents p < 0.0001) hours, respectively. c: K562 survival curve. K562 cells were treated in the absence of serum. The
Western blot analysis shows 100% inhibition of CREB expression with siRNA at 48 (* represents p < 0.0001) and 72 (* represents p < 0.0001) hours. d: K562 cells
were transfected with TKO reagent alone, 100 nM luciferase siRNA, or 100 nM 3# CREB siRNA at 0, 24, and 48 hr. Western blot analysis shows no CREB
inhibition with luciferase siRNA, confirming the specificity of 3# CREB siRNA. Experiments were performed in triplicate and on three separate days.
Error bars represent the standard deviation for each sample measured in triplicate.compared to control cells (p < 0.05, Figure 2B). These results
indicate that overexpression of CREB results in increased
transcriptional activity of promoters that contain the CREB re-
cognition sequence.
The growth and survival of hMRP8-CREB overexpression in
myeloid cell lines was assessed. Our results demonstrated that
both K562 and NFS-60 cells expressing CREB grew faster
in exponentially growing cultures and survived longer (after
reaching saturation density) under normal growth conditions
and in serum-free conditions (p % 0.05, Figure 2C). Cells that
overexpressed CREB also had a 40% increase in numbers of
cells in S phase by Brdu incorporation (p < 0.05, Figure 2D).
To test if overexpression of CREB perturbs differentiation
pathways in myeloid cells, we induced K562 cells to differenti-
ate along the erythroid lineage using sodium butyrate (Pace
et al., 2003; Yu et al., 2003). Approximately 25% of parental
K562 cells stained positive for benzidine after 72 hr (Figure 2E,
left). In contrast, 5%–8% of clones that overexpressed CREB
stained positive for benzidine (p < 0.04). Cell growth was not
affected by sodium butyrate treatment (Figure 2E, right). These
results indicate that CREB overexpression inhibits differenti-
ation.
CREB downregulation suppresses myeloid cell
proliferation and survival
Our previous results demonstrated that ectopic expression of
CREB resulted in enhanced cell proliferation and survival in
myeloid cell lines. Next, we used small interfering RNA (siRNA)
to downregulate expression of endogenous CREB in K562 and
TF-1 human myeloid leukemia cell lines. Addition of CREB
siRNA, but not control siRNA, at a concentration of 100 nM
significantly inhibited the growth of K562 at 72 hr (Figure 2Fa;
asterisk represents p = 0.038) and TF-1 cells at both 48 and
72 hr (Figure 2Fb; asterisk represents p = 0.0001). CREB ex-
pression decreased by 60% to 90% at 72 hr following siRNA
treatment in regular growth media and following serum depri-
vation (Figure 2F). Inhibition in survival was observed at 48 and
72 hr (p < 0.0001). In contrast, inhibition of nonspecific siRNA
to luciferase did not inhibit the growth of K562 cells after 72 hr
(Figure 2Fd). Levels of CREB were not affected by the addition
of luciferase or Jab1 siRNA (data not shown). These results
suggest that CREB regulates growth and survival of myeloidCANCER CELL : APRIL 2005CREB overexpression in vivo leads
to aberrant myelopoiesis
To study CREB overexpression in vivo, we generated trans-
genic mice in which overexpression of CREB was specifically
targeted to the macrophage/monocyte lineage. The transgene
contains the CREB cDNA under the control of the human
MRP8 promoter. MRP8 is expressed in immature myeloid cells
of the bone marrow and myeloid cells in the splenic red pulp
and marginal zone, in addition to monocytes and blood neutro-
phils (Lagasse and Weissman, 1992; Lagasse and Weissman,
1996; Lagasse and Weissman, 1997).
CREB transgenic mice were identified by Southern blot
analysis of tail DNA (Supplemental Figure S2A). Three indepen-
dent lines with germline transmission were established from
five founders. Tissue specific expression was confirmed with a
3- to 4-fold increase in CREB protein levels (Supplemental Fig-
ures S2B and S2C). Peripheral blood and bone marrow from
the transgenic mice at 3.5 and 13 months of age showed in-
creased white blood cell count compared to age-matched lit-
termate controls, the most consistent being in the monocyte
lineage (Figures 3A and 3B and Table 2). The monocyte count
was higher in double transgenic mice, i.e., CREB transgenic
mice bred with other CREB transgenic mice, compared to sin-
gle transgenic mice. No differences were observed in the he-
matocrit or platelet count (data not shown). In mice less than
1 year of age, the histopathologic analyses of spleen, bone
marrow, lymph nodes, and liver were normal. However, 6/7
CREB transgenic mice and 0/11 normal age-matched litter-
mate controls between the ages of 14 and 20 months devel-
oped myeloproliferative syndrome with splenomegaly and ab-
errant myeloid proliferation in the spleen (p = 0.0004 by Fisher’s
exact test; Figure 3B). Interestingly, an increase in peripheral
blood lymphocytes in addition to myeloid cells was observed,
which was confirmed by FACs analysis (Table 2 and Figure 3C).
Work by others showed that increased numbers of activated
monocytes that express hMRP8 resulted in stimulation of T
helper cell production due to cytokines that are released in
mice (Roth et al., 1993). Several of the CREB transgenic mice
but not control mice developed dermatitis, as previously re-
ported (Frantzen et al., 1993; Roth et al., 1993).
To look for alterations in the myeloid progenitor cells of355
A R T I C L EFigure 3. Peripheral blood counts from CREB transgenic mice
A: Monocyte counts were determined from orbital bleeds taken from transgenic (red) or age-matched control littermates (blue) at different ages (mice
1–12 are 4 months of age, mice 12–14 are 6 months of age).
B: Spleens from a CREB transgenic mouse and normal age-matched, littermate control. The splenic architecture is abnormal (low power); aberrant myeloid
cells are also present (high power).
C: FACS staining of bone marrow and peripheral blood from CREB transgenic mice or normal controls.
D: Left: CREB overexpression results in myeloid proliferation and immortalization of hematopoietic progenitor cells. A photomicrograph of colonies in
methylcellulose at day 5 after culture of control (upper panel) and transgenic bone marrow (lower panel) is shown. Middle: colonies at day 12 after
plating showing fully differentiated CFU-GMs in the normal marrow in contrast to the more diffuse proliferating immature colonies in the CREB transgenics.356 CANCER CELL : APRIL 2005
A R T I C L ETable 2. Summary of the peripheral blood counts from two founder lines at different ages
Segmented
WBC (×103/ml) neutrophils (×103/l) Lymphocytes (×103/l) Monocytes (×103/l) Eosinophils (×103/l) Basophils (×103/l)
Genotype [median] [median] [median] [median] [median] [median]
Wild-type (3.5 2.3–9.3 [4.47] 0.35–2.0 [1.0] 1.82–6.71 [3.06] 0.05–0.75 [0.22] 0.04–0.9 [0.21] 0–0.2 [0.05]
months), n = 14
Transgenic (3.5 4.62–27.28 [6.28] 0.41–2.59 [0.94] 2.5–22.0 [4.56] 0.42–4.3 [0.5] 0.02–0.83 [0.13] 0–0.09 [0.03]
months), n =11
Wild-type (13 2.5–8.1 [4.0] 0.25–1.9 [0.6] 1.5–7.01 [3.1] 0.05–0.48 [0.25] 0.04–0.5 [0.21] 0–0.1 [0.04]
months), n = 10
Transgenic (13 4.9–18.6 [7.61] 0.7–4.5 [1.74] 2.6–11.7 [4.79] 0.23–1.92 [0.5] 0–1.2 [0.13] 0–0.08 [0.04]
months), n = 12we plated bone marrow cells (10 ) from CREB transgenic or duced in response to CREB activation in other systems (Mayr
Right: a photomicrograph showing the colonies after serial replating is shown. Experiments were performed in triplicate with bone marrow from five
transgenic mice derived from two independent lines. These results indicate that the myeloid progenitor cells from CREB transgenic mice have increased
proliferative potential.
E: Increased numbers of colonies from CREB transgenic mouse bone marrow at days 5 and 12, and after replating. These results were reproducible in
three experiments, and experiments were performed in triplicate. The difference was statistically significant (p < 0.05). Error bars represent the standard
deviation for each sample measured in triplicate.
F: Colony assays with M-CSF. Progenitor cells were grown in methylcellulose containing M-CSF (10 ng/ml). Red (right bar) represents bone marrow from
CREB transgenic mice; green (left bar) represents age-matched littermate control. Error bars represent the standard deviation for each sample measured
in triplicate.
There is a statistically significant increase in the number of CFU-M colonies from transgenic mice (p < 0.05).
G: Morphology of cells in the methylcellulose colonies. Cytospin preparations of cells from transgenic and normal colonies stained with Wright-Giemsa.
The cells from the transgenic marrow show an increased number of immature cells, in contrast to the differentiated monocytic cells of the normal marrow.
H: Immunophenotypic analysis of cells from colony assays demonstrated expression of c-Kit, Gr-1, and Mac-1.
I: Growth factor-independent colony-forming activity of CREB transgenic bone marrow cells was demonstrated in two independent experiments in two
different transgenic lines. The cells from all the colonies in the methylcellulose cultures were pooled and counted. The values shown are the mean of
duplicate cultures. Bone marrow cells from CREB transgenic mice have a statistically significant higher cell number compared to control mice (indicated
by *) in the absence of growth factors.
J: CREB overexpression leads to blast-like colonies. Microscopic appearance (top left), cytospins (bottom left), and FACS (right) following tertiary replating
of bone marrow progenitor cells in methylcellulose containing SCF, IL-3, and IL-6. CREB Tg1 and 2 represent two different founder lines. FACS analysis shows
>99% cells were c-kit-positive and <1% were GR-1- and MAC-1-negative. These experiments were performed in triplicate on three separate days.cellulose containing SCF, IL-6, and IL-3 or the lineage-specific
growth factor, M-CSF. Bone marrow cells from transgenic mice
formed robust colonies earlier and formed significant colony-
forming units (CFU-GM or CFU-M) when compared to bone
marrow from age-matched, nontransgenic littermates (p <
0.05; Figures 3D–3F). A significant increase in colony-forming
units was also observed (p < 0.001; Figures 3E and 3F). Cells
from colony assays also overexpressed CREB (Supplemental
Figure S2D). To assess self-renewal of progenitors from CREB
transgenic mice, we replated bone marrow cells (104) in
methylcellulose that contained growth factors SCF, IL-6, and
IL-3, and counted the colonies after 12 days. Bone marrow
cells from transgenic mice were highly successful in repopulat-
ing the methylcellulose (Figure 3D, right panel, and Figure 3E).
In contrast, bone marrow cells from control mice were unable
to grow after serial replating.
Cytospins of cells from colonies at day 7 showed the pres-
ence of more immature myeloid cells compared to the control
cells (Figure 3G). FACs analysis showed that the colonies con-
sisted of cells that were 50% c-Kit-positive, 83% Gr-1-positive,
and 67% Mac-1-positive (Figure 3H). These results suggest
that the bone marrow from transgenic mice contains myeloid
progenitor cells with an increased proliferative potential when
grown within the proper environment.
To determine whether increased CREB expression confers
growth factor independence in hematopoietic progenitor cells,
4CANCER CELL : APRIL 2005normal mice in methylcellulose without GM-CSF, IL-3, or IL-6.
We observed a 10-fold increase in the number of cells cultured
in the absence of cytokines in all founder lines compared to
normal bone marrow (for Tg mouse1, p = 0.0012; for Tg mouse
2, p = 0.0050). The phenotype was similar to cells grown in
the presence of cytokines. Cells from transgenic mice survived
longer in liquid culture containing IL-3, but did not grow (data
not shown). Therefore, CREB overexpression promotes growth
factor-independent proliferation and survival (Figure 3I).
Among the hallmarks of leukemia are immortalization and the
continued proliferation of immature blast cells without differen-
tiation. After tertiary replating of CREB transgenic mouse bone
marrow in methylcellulose containing SCF, IL-6, and IL-3, we
observed the emergence of colonies (mean of 96 ± 3.5) that
consisted of larger, homogeneous-appearing, immature blast
cells that were >99% c-Kit-positive and <1% Gr-1, Mac-1-pos-
itive (Figure 3J). Therefore, persistent expression of CREB
leads to a blast-like phenotype in the absence of differenti-
ation.
Cyclin A1 is upregulated in myeloid leukemia
cells that overexpress CREB
We previously demonstrated that CREB increased cell prolifer-
ation, cell cycle progression, and survival (Figures 2C and 2D).
To investigate possible mechanisms by which CREB causes
this phenotype, we examined known target genes that are in-357
A R T I C L Eand Montminy, 2001). Cyclin A1 has been reported to be a
CREB target gene and regulates G1 to S transition through ac-
tivation of CDK2 (Woo and Poon, 2003). CREB directly binds
the CRE in the cyclin A1 promoter and increases transcription
of cyclin A1 upon activation of CREB (Desdouets et al., 1995;
Kothapalli et al., 2003; Mayr and Montminy, 2001). In our ex-
periments, cyclin A1 protein levels were elevated 3-fold in the
myeloid cells that overexpress CREB, but not in control cells
(Figures 4A and 4B). However, Bcl-2 levels remained the same
in CREB-positive and control cell lines (Figure 4A). To study
cyclin A1 levels in primary cells, we looked at expression by
Western blot analysis using lysates from CREB-positive and
-negative AML patients, and nonleukemic controls. Our results
showed that in the AML samples that overexpressed CREB, a
corresponding increase in the cyclin A levels was observed
(Figure 4C). However, we did not see cyclin A1 expression in
the bone marrow of AML patients who were CREB-negative or
in normal samples; this suggests that CREB expression and
cyclin A1 are coregulated. These results were confirmed with
mouse bone marrow cells from colony assays (Supplemental
Figure S2D).
To study the possibility of cyclin A1 upregulation down-
stream of CREB, we examined transcriptional activation of
cyclin A1 in CREB-overexpressing NFS60 cells. A luciferase
reporter construct containing the cyclin A1 promoter with theFigure 4. Analysis of potential CREB target genes
A and B: Western blot analysis was performed with CREB-overexpressing
K562 cells (A), NFS60 cells (B), or controls. Cyclin A1 but not Bcl-2 protein
levels were increased in most CREB-overexpressing clones compared to
controls.
C: Western blot analysis of protein lysates from CREB-positive and CREB-
negative AML patients using cyclin A1 antisera. Cyclin A1 expression
was observed in CREB-positive, but not CREB-negative or nonleukemic,
samples.
D: CREB-overexpressing clones demonstrated increased cyclin A1 pro-
moter activity. NFS60 cells were transiently transfected with a cyclin A1
promoter luciferase construct. Experiments were performed in triplicate on
three separate days. Error bars denote the standard deviation for each
sample. A statistically significant increase in cyclin A1 transactivation was
observed (indicated by * and ^).358CRE was transfected into NFS60 cells that overexpressed
CREB. A significant increase in relative luciferase activity was
observed in the CREB-overexpressing cells compared to con-
trol cells (p < 0.05; Figure 4D). Our results suggest that CREB
overexpression leads to upregulation of a known CREB target
gene, cyclin A1, thereby promoting aberrant cell cycle pro-
gression and increased proliferation.
Discussion
Novel role of CREB in cell transformation
CREB has been shown to be a critical regulator of proliferation
and survival in normal neuronal development (Haywitz and
Greenberg, 1999; Mayr and Montminy, 2001). CREB also in-
duces proliferation of T cells in response to a variety of stimuli
(Kuo and Leiden, 1999). Transgenic mice expressing dominant
negative CREB (serine133 to alanine) had normal T cell devel-
opment but displayed a profound defect in T cell proliferation
following stimulation with α-CD3 and PMA. Unlike myc, which
appears to be sufficient for malignant transformation to cause
leukemia (Langenau et al., 2003), metastatic prostate cancer
(Ellwood-Yen et al., 2003), and osteogenic sarcoma (Fukunaga
et al., 1993), CREB appears to be in a different class of preon-
cogenic proteins that contribute to the malignant phenotype.
We previously demonstrated that CREB is overexpressed in a
subset of AML patients. In this paper, we report that aberrant
expression of CREB leads to enhanced survival and growth
properties in vitro and in vivo.
The precise mechanism of CREB overexpression is not
known. Our results suggest that CREB is upregulated at both
the protein and mRNA levels. FISH analysis of CREB-positive
AML blasts suggests that an increased copy number of the
CREB gene is one possible mechanism for CREB overexpres-
sion in a subset of AML patients.
CREB overexpression results in a blast-like phenotype
of hematopoietic progenitor cells
CREB has been shown to promote survival of neuronal cells.
We report that CREB overexpression is sufficient for immortali-
zation, growth factor-independent proliferation, and blast-like
phenotype. Recently, retroviral transduction of bone marrow
progenitor cells with a dimerizable fusion protein, MLL-FKBP,
was shown to result in immortalization of hematopoietic pro-
genitor in methylcellulose replating assays (Martin et al., 2003).
In addition, mouse bone marrow cells transduced with MLL-
AF9, a fusion protein associated with AML, transformed cells
to generate myeloblastic cell lines capable of growing in liquid
culture containing only IL-3. Bone marrow from our hMRP8-
CREB transgenic mice demonstrated increased hematopoietic
colony size and numbers in colony assays compared to non-
transgenic control mice. Furthermore, these myeloid progenitor
cells were capable of sustained survival in liquid culture con-
taining only IL-3, although cells did not proliferate to a signifi-
cant degree (data not shown). Taken together, these results
suggest that CREB alone is sufficient to promote survival of
myeloid progenitor cells and contributes to proliferative poten-
tial and immortalization of these cells in culture.
Potential mechanism: Overexpression of CREB leads
to inappropriate expression of cyclin A
We propose that elevated expression of CREB leads to upregu-
lation of CREB target genes that control cell proliferation andCANCER CELL : APRIL 2005
A R T I C L Esurvival as one potential mechanism for the phenotypes ob-
served. We hypothesize that CREB overexpression results in
inappropriate expression of cyclin A1, leading to cell cycle pro-
gression. This is further confirmed in primary leukemia blast
cells from patients with AML, in which CREB-positive AML
blasts also overexpress cyclin A1. Recent work has shown that
overexpression of cyclin A1 under the control of the myeloid-
specific cathepsin G promoter in mice leads to myeloid leuke-
mia at a low frequency after a prolonged latency (Liao et al.,
2001). Furthermore, cyclin A1 overexpression has been de-
tected in leukemia samples from a subset of AML patients as
well as in normal CD34+ cells (Muller-Tidow et al., 2001; Yang
et al., 1999). These results are consistent with our observa-
tions. The fact that CREB induces cyclin A1 explains enhanced
proliferation and increased numbers of cells in S phase, but
not increased survival. It is likely that additional target genes
that are induced by CREB activate downstream signaling path-
ways that promote survival.
CREB is not sufficient to induce leukemia
In vitro, CREB-overexpressing cells acquire a blast-like pheno-
type. Although CREB is not sufficient to induce acute leukemia
in vivo, overexpression does lead to a myeloproliferative disor-
der. Similar observations have been made with translocations
such as AML1-ETO, which requires additional mutations for
leukemia to develop in mice (Yuan et al., 2001). Oncogenic K-ras
expression in myeloid progenitor cells has been shown to re-
sult in myeloproliferative disease, but not AML (Braun et al.,
2004; Chan et al., 2004). We conclude that CREB contributes
to the positive growth phenotype of myeloid cells, but not to
the point of overt transformation in a mouse model. Additional
“hits” or steps are required for leukemia to develop.
CREB overexpression is associated with increased
relapse or persistent disease
Our results suggest that CREB may be associated with high
risk AML, and that its expression can be used to follow certain
patients during therapy for evidence of relapse or resistant dis-
ease. Recently, overexpression of cyclin A1 was found to be
associated with improved survival in AML patients (Nakamaki
et al., 2003). We hypothesize that in a subset of myeloid leuke-
mia blast cells, CREB overexpression occurs, resulting in addi-
tional cell cycle abnormalities and increased genomic insta-
bility (see model, Figure 5). Clearly, additional target genes
upregulated by CREB and multiple signaling pathways are in-
volved in clonal selection and leukemic progression in AML.
Experimental procedures
Cell lines and transfection
K562, TF-1 cells were obtained from the American Type Culture Collection
(ATCC) and maintained in Iscoves medium (Invitrogen) with 10% fetal bo-
vine serum (FBS), and RPMI with 10% FBS and rhGM-CSF (Amgen),
respectively. NFS 60 cells were a gift from Dr. Jim Ihle, and were maintained
in RPMI (Invitrogen) supplemented with 10% FBS and IL3. The hMRP8-
CREB construct was transfected into the various cell lines as previously
described (Mora-Garcia and Sakamoto, 2000). PUC-19 neo plasmid (5 g)
was cotransfected with the CREB plasmid. After transfection, 100 cells
were plated in 24 cell wells and selected with G418 (Invitrogen). Several
clones were thus generated and tested for CREB expression by Western
blot analysis.CANCER CELL : APRIL 2005Figure 5. Model summarizing the role of CREB in myeloid cell transformation
CREB is expressed at higher detectable levels in a subset of AML blast cells,
which results in upregulation of CREB target genes and increased cell cy-
cle progression and proliferation and decreased differentiation.Patient selection and bone marrow isolation
Isolation of mononuclear cells from the bone marrow from AML patients
was as previously described (Crans-Vargas et al., 2002).
Protein extraction and Western blot analysis
Cell lysates were made from 1 × 106 cells (cell culture and primary cells),
and Western blot analysis was performed as previously described (Crans-
Vargas et al., 2002; Lee et al., 1995; Lin et al., 1998; Lin and Sakamoto,
2001). The following antibodies were used: Polyclonal anti-CREB and anti-
phospho-CREB (UBI, NY), anti-Actin, Bcl2, cyclin A1, and β-tubulin (Santa
Cruz, CA).
Immunohistochemical studies
Bone marrow was obtained from both pediatric and adult patients with AML
and ALL following informed consent. Bone marrow aspirate slides were
fixed in 4% paraformaldehyde for 20 min, and then rinsed in PBS and Tri-
ton-X 100 for 10 min each. To eliminate endogenous peroxidase activity,
slides were incubated in 0.3% hydrogen peroxide for four min, followed by
blocking with 5% BSA/PBS for 45 min to reduce background staining. After
removing the blocking solution, 50 l of the primary antibody (anti-CREB
rabbit polyclonal IgG, UBI, Lake Placid, NY) was added in a dilution of
1/50 in 0.1% Triton X-100. The slides were then incubated overnight at
4°. After two 10 min washes in 1× TBS, 50 l of the secondary antibody
(Biotinylated Goat Anti-Rabbit) was applied in a 1/300 dilution in 0.1% Triton
X-100 for 30 min. After a quick wash with 1× TBS-T, 50 l of peroxidase-
conjugated streptavidin/HRP in a 1/300 dilution in 0.1% Triton X-100 was
applied for 30 min. The slides were then washed in water for 10 min, and
100 l of hematoxylin counterstain was applied for 30 s. Slides were then
examined under a microscope for CREB staining.
RNA isolation and real-time RT-PCR
Total RNA was isolated from bone marrow tissue (2 × 106 to 107 cells per
sample) by the acid guanidium thiocyanate-phenol-chloroform (TRIzol;
Gibco BRL, Gaithersburg, MD, USA) method (Chomczynski and Sacchi,
1987) and quantified using UV absorbance at 260 nm on a spectrophotom-
eter (DU640; Beckman Coulter, Fullerton, CA, USA.) cDNA was synthesized
using the SuperScript III system for RT-PCR (Invitrogen), as per manufactur-
er’s instructions. Reactions were reproduced three times and performed in
20 l using 5 g of total bone marrow RNA and oligo (dT) primer. cDNA was
precipitated with 3 M NaOAc (pH 5.0) and 100% EtOH and resuspended in
200 l of water. Target primers and probe sequences for CREB amplification
were designed using Primer Express Software. Forward primer: 5#-AAGCT
GAAAGTCAACAAATGACAGTT-3# and reverse primer: 5#-TGGACTGTCTG
CCCATTGG-3#. The TaqMan probe sequence (5#-CTCATGCGACGTCAT
CTGCTCCCA-3#) was labeled with fluorescent reporter dye VIC. Each 25359
A R T I C L El of reaction mixture contained 12.5 l of TaqMan Master Mix (2×) (Applied
Biosystems), 7.2 M primers, and 2 M probe. For cell sorting experiments,
total RNA was extracted from the different sorted subpopulations using
RNA easy kit (Qiagen Inc, CA) and reverse transcribed using superscript
III reverse transcriptase (Invitrogen Corp., CA) according to manufacturer’s
instructions. Real-time RT-PCR analysis was performed with an automated
sequence detection system (ABI 7700) with TaqMan dual-label fluorogenic
detection. The GAPDH gene was used as the internal control to test the
integrity of the RNA and for standardization. The data were analyzed using
the comparative Ct method (Delta Ct), and results are shown as fold induc-
tion of mRNA. All experiments were performed in triplicate.
Fluorescence in situ hybridization (FISH)
BAC RP11-17I6, which includes the creb1 gene (http://www.ncbi.nlm.nih.
gov/mapview/maps.cgi?gnl=NT_005403&MAPS=cntg-r,loc,clone&query=
RP11-17I6&ABS_ZOOM=3M), was purchased from Invitrogen and labeled
with 11-dUTP-digoxigenin (Roche Molecular). The labeled probe was hy-
bridized to metaphase chromosomes prepared from normal controls (fresh
blood) and patient interphase nuclei (frozen blood lymphocytes) following
standard cytogenetic protocols (Rao et al., 1992). Briefly, 40–60 ng of the
labeled probe was hybridized to cells overnight. The probe was first hybrid-
ized to normal control metaphases to determine and confirm its localization
on chromosome 2q. At least 25 metaphases were examined per hybridiza-
tion. The hybridized probe was detected by FITC conjugated anti-digoxy-
genin antibodies, and successive layers of fluorescence-conjugated anti-
body were used to obtain easily detectable signals. About 250 interphase
nuclei from the patient samples were analyzed. The slides were counter-
stained with DAPI in an antifade solution and analyzed using a Zeiss Axio-
phot microscope equipped with epifluorescence filters for simultaneous
FITC and DAPI observations. The images were captured on an Applied Im-
aging Image analysis system.
Relapse and survival analysis
With Medical Institutional Review Board approval, medical records were
reviewed on 34 AML patients over age 18 whose initial marrows had been
analyzed for CREB expression (two diagnosed in years 1993–1997, 18 from
1998–2000, and 14 from 2001–2003). All patients had received Ara-C/Dau-
nomycin-based chemotherapy generally within 1–2 days following diagno-
sis. Date of diagnosis, age, gender, initial WBC, percent blasts, percentage
CD33+ and CD34+ cells, FAB classification of AML subtype, and cytoge-
netics were recorded. The first date upon which peripheral blood showed
evidence of persistent disease was recorded for any patient not in remission
after initial induction chemotherapy. Otherwise, the date of first relapse (if
any) was recorded. Total followup time was based on the last known date
of patient contact. Comparisons of categorical or continuous variables be-
tween CREB groups were tested by Fisher’s exact test or rank sum test,
respectively. Kaplan-Meier analysis was used to estimate time until first re-
lapse or persistent disease, event-free survival, and overall survival. Exact
logrank tests, with and without stratification, were used to compare curves
between CREB expression groups. Cox proportional hazard regression
models were also used to test the significance of CREB expression after
controlling for other covariates and stratifying on cytogenetic prognosis.
Prognostic stratification of marrow cytogenetics was by classification as
high risk, intermediate or unknown, and low risk (Newland, 2002; Rohatiner
and Lister, 2002).
BrdU incorporation
NFS60 and K562 cells were cultured in serum-free conditions for 12 and
24 hr, respectively, to synchronize the cells. The cells were then washed
and resuspended in regular medium containing 10% FBS, and BrdU (BD
Biosciences) at a final concentration of 10 M was added to the cells. The
cells were then harvested at 0, 1, 6, 12, and 24 hr after labeling for analysis
by flow cytometry. The BrdU-pulsed cells were fixed and stained with FITC-
anti-BrdU antibody using manufacturer’s protocol (BD Pharmingen BrdU
Flow Kit). Total DNA content was measured by staining with 7AAD, and flow
cytometric analysis was performed using the BD FACScan and CellQuest
software.
Differentiation of K562
CREB-overexpressing clones or parental K562 cells (4 × 105 cells/ml) were
cultured with sodium butyrate (1 mM final concentration) or control in Is-360coves media with 10% FBS. At 0, 24, 48, and 72 hr, cells were harvested,
stained with benzidine (Sigma Inc., St. Louis, MO), and then counted. Five
microliters of 30% hydrogen peroxide was added per milliliter of cells, and
the cells were then incubated at 37°C for 5 min. One milliliter of phosphate-
buffered saline (PBS) was added to stop the reaction. The total number of
cells and number of positively stained cells was counted and the percen-
tage calculated. Statistical analysis was performed using the JmpIn soft-
ware program.
CAT and luciferase reporter assays
The preparation of the −600 egr-1 CAT and β-galactosidase constructs was
as previously described (Mora-Garcia and Sakamoto, 2000; Sakamoto et
al., 1994). Parental K562 and CREB clones were transiently transfected with
the CAT and β-galactosidase constructs (Mora-Garcia and Sakamoto, 2000;
Sakamoto et al., 1994). Fold stimulation was determined, and statistical
analysis was done using JmpIn software. The −1299 to +145 cyclin A1
luciferase construct was obtained from Dr. Carsten Muller-Tidow, Germany.
The NFS60 parental and clones were transfected with the cyclin A reporter
construct (15 g) and β-galactosidase reporter plasmid (5 g) by electro-
poration. After 24 hr, cells were lysed in luciferase cell lysis buffer, and lucif-
erase assay performed according to manufacturer’s instructions (Promega).
siRNA experiments
A 19-nucleotide (nt), CREB-specific, double-stranded siRNA sequence 5#-
GAGAGAGGUCCGUCUAAUG-3# was identified and synthesized by Dhar-
macon Industries (Lafayette, CO). The selection criteria for our CREB siRNA
included: AAN19TT format, G-C content 30%–50%, >2 nt unique by Gen-
Bank Blast comparison, and confirmation of no sequence polymorphisms
against the NCBI SNP database. Transient transfections were performed
with the Trans-it-TKO reagent from Mirus Inc. Cells (0.5 × 106 cells/ml) were
placed in 1 ml of Iscoves media with heat-inactivated 10% FBS. CREB
siRNA was added at a final concentration of 100 nM and incubated for 20
min. The complex was then added to the cells in 6-well plates and gently
mixed. Media changes were performed every 24 hr with repeat addition of
siRNA complex. Cells were counted for viability every 24 hr and lysates
were prepared with boiling SDS-Laemmli buffer. To assess cell survival,
cells were placed in media containing 0.5% bovine serum albumin (BSA)
instead of fetal calf serum. The statistical analyses for p values were ob-
tained using the JmpIn program.
Pathology
Serial blood counts were performed on the transgenic mice. Peripheral
blood (100–500 l) was collected in EDTA-coated Microvet (Becton-Dickin-
son) tubes from orbital eye bleeds. Complete blood counts and differential
were analyzed at the MU-RADIL facility of University of Missouri using Hem-
avet 850 and stained blood smears, respectively. Bone marrow was ob-
tained from the transgenic and normal mice after euthanasia. Femurs and
tibia from mice were dissected and bone marrow was flushed out in 1–2 ml
of Iscoves medium with 2% fetal bovine serum. The cells were resuspended
to make a single cell suspension, and nucleated cells were counted after
dilution in 3% acetic acid using a hemocytometer.
Colony assays
Bone marrow cells at a dilution of 0.3 ml at 2 × 105 cells/ml were suspended
in 3 ml of methyl cellulose-containing growth factors (Methocult 3534, Stem
Cell Technology, Vancouver, Canada). The mixture was plated in 1.1 ml du-
plicate cultures. The colonies were observed every day and counted on day
5 and day 12. For self-renewal experiments, the colonies were harvested
and replated on fresh methylcellulose containing growth factors, and colony
formation was observed. Triplicate platings were performed on day 12. Cel-
lular morphology of the colonies was evaluated with cytospin preparations
and Wright-Giemsa staining.
Flow cytometric analysis
Cells from the colonies were harvested and washed, and single cell suspen-
sions were prepared. Approximately 1 × 106 cells were stained for 30 min
on ice with monoclonal antibodies, washed in staining buffer, and analyzed.
The antibodies used were FITC-conjugated Gr-1, Mac-1, and c-Kit (Phar-
mingen, CA). Flow cytometry was performed with a FACScan cytometerCANCER CELL : APRIL 2005
A R T I C L E(Becton-Dickinson, CA). A minimum of 10,000 events were acquired and
analyzed with CellQuest software.
Supplemental data
Supplemental data for this article can be found at can be found at http://
www.cancercell.org/cgi/content/full/7/4/351/DC1/.
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